Senti Biosciences Inc (SNTI)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Senti Biosciences Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 0.37 $ — 2% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -82.7% failed
- More than 10% revenue growth is expected for the coming year 50.0% passed
- Share count grows by less than 3% a year 271.1% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion -16,431.8% failed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 48 m failed
- Return on capital at 15% or higher, or up versus two years ago -171.1% failed
- Insiders hold at least 10% or are net buyers 47.9% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 3,413.5% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.33 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.02 | – | 6 | 1,658.60 | -10.40 | -14 | -14 |
| 2025: Q1 | -0.45 | – | 0 | -100.00 | – | -14 | -14 |
| 2025: Q2 | -0.47 | – | 0 | – | – | -13 | -13 |
| 2025: Q3 | -0.58 | – | 0 | – | – | -9 | -9 |
| 2025: Q4 | -0.46 | – | 0 | -99.60 | -65,759.10 | -7 | -7 |
| 2026: Q1 | -0.14 | – | 0 | – | -26,381.20 | -8 | -8 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Senti Biosciences Holdings, Inc., ein Biotechnologieunternehmen in der klinischen Phase, entwickelt Zell- und Gentherapien, die mit seinen Gene-Circuit-Plattformtechnologien für Patienten mit unheilbaren Erkrankungen konstruiert werden.
| Employees | 39 |
|---|---|
| Headquarters | South San Francisco, CA |
| Website | sentibio.com |
| IPO Date | 9. Jun 2022 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Timothy K. Lu M.D., Ph.D. | Co-Founder, CEO & Director | 1981 |
| Kanya Rajangam M.D., Ph.D. | President, Head of Research & Development and Chief Medical Officer | 1974 |
| James J. Collins Ph.D. | Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director | 1966 |
| Jay Cross | Chief Financial Officer | 1971 |
| Wilson Wong Ph.D. | Scientific Co-Founder & Member of Scientific Advisory Board | – |
| Faraz Siddiqui | Senior Vice President of Technical Operations | – |
| Robert H. Cutler J.D. | Senior VP & Head of Legal Affairs | 1968 |
| Thomas P. Chung | Vice President of Strategic Finance & Corporate Development | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.